Variables | Frequency (N = 533) | Proportion (percentage) |
---|---|---|
Current retention at 12 months | ||
Active | 511 | 95.9 |
Died | 4 | 0.8 |
Transferred out | 8 | 1.5 |
Lost > 28 days | 10 | 1.9 |
Current viral load suppression | ||
Non-suppressed | 134 | 25.1 |
Suppressed | 399 | 74.9 |
Adherence scores | ||
Good | 494 | 92.7 |
Fair | 27 | 5.1 |
Poor | 12 | 2.3 |
Baseline WHO clinical stage | ||
Clinical stage I | 50 | 9.4 |
Clinical stage II | 438 | 82.2 |
Clinical stage III | 32 | 6.0 |
Clinical stage IV | 13 | 2.4 |
Baseline CD4 count | ||
< 200 copies | 66 | 12.4 |
> = 200 copies | 209 | 39.2 |
Not done | 258 | 48.4 |
Current ART regimen | ||
ABC-3TC-DTG | 88 | 16.5 |
AZT-3TC-DTG | 29 | 5.4 |
TDF-3TC-DTG | 406 | 76.2 |
TDF-3TC-LPV/r | 1 | 0.2 |
Other | 9 | 1.7 |
Current ART line | ||
First line | 449 | 84.2 |
Second line | 71 | 13.3 |
Third line | 13 | 2.4 |
Current DSDM approach | ||
CCLAD (community client-led ART Delivery) | 25 | 4.7 |
CDDP (Community drug delivery points) | 106 | 19.9 |
FBG (facility-based groups) | 354 | 66.4 |
FBIM (facility-based individual management) | 40 | 7.5 |
FTDR (Fast-track drug refills) | 8 | 1.5 |
MUAC (Mid-upper arm circumference) | ||
Green | 498 | 93.4 |
Yellow | 23 | 4.3 |
Red | 12 | 2.3 |
TB status | ||
No signs and symptoms | 498 | 93.4 |
Presumptive | 28 | 5.3 |
TB diagnosed | 7 | 1.3 |
OVC (orphaned and vulnerable children) status | ||
Ever enrolled | 323 | 60.6 |
Never enrolled | 210 | 39.4 |
Benefited from OVC services (N = 323) | ||
No | 62 | 19.2 |
Yes | 261 | 80.8 |
MMD (multi-month dispensing) | ||
< 3_months | 59 | 11.1 |
3 to 5 months | 273 | 51.2 |
More than 5 months | 201 | 37.7 |
Disclosure status | ||
Yes | 522 | 97.9 |
No | 11 | 2.1 |